Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY

Appetite and General Nutritional Disorders Clinical Trial

Official title:

The Functional Significance of Gut-expressed Taste Receptors in the Secretion of Glucagon-like Peptide-1 and Peptide YY

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01088841
• Other study ID #: EKBB 69/04.01
• Status: Completed
• Phase: Phase 1
• First received: March 16, 2010
• Last updated: February 22, 2011
• Start date: April 2009
• Est. completion date: March 2010

Study information

• Verified date: February 2011
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of GI satiety peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gut.

Description:

There is strong evidence that taste signaling mechanisms identified in the oral epithelium also operate in the gut. It is suggested that open-type enteroendocrine cells directly sense nutrient via alpha-gustducin coupled taste receptors to modulate the secretion of glucagon like peptide-1 (GLP-1) and peptide YY (PYY). Several nutrient responsive G-protein coupled receptors have been identified in the human gut, including the sweet taste responsive T1R2/T1R3 heterodimer, the amino acid/umami responsive T1R1/T1R3 as well as GPR120 for unsaturated long-chain free fatty acids.The functional significance of sweet taste receptors in glucose stimulated secretion of GLP-1 and PYY will be determined by intragastric infusion of 75 g glucose with different concentrations of lactisole (150 ppm, 300 ppm and 450 ppm)in a double blind, 4-way crossover trial including 16 healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: March 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy subjects

• BMI of 19.0-24.5

• Age 18-40

• stable body weight for at least 3 month

Exclusion Criteria:

• smoking

• substance abuse

• regular intake of medication

• medical or psychiatric illness

• gastrointestinal disorders or food allergies

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Appetite and General Nutritional Disorders
• Hormone Replacement
• Nutrition Disorders

Intervention

Dietary Supplement:
• lactisole
lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube

Locations

Country	Name	City	State
Switzerland	University Hospital Basel, Clinical Research Center	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gastrointestinal peptide secretion		2 hours blood sampling	No